A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022 an anti-TIM-3 Monoclonal Antibody in Patients with Advanced Solid Tumors
Brief description of study
If you have been diagnosed with advanced solid tumors, primarily advanced or metastatic (cancer spreading to other areas within the body) sin cancer; you may qualify to participate in a study evaluating the anti-tumor activity of TSR-022 monotherapy, an anti-TIM3 monoclonal antibody (a blocker of PD-L1 activity). The main goal of this phase I study is to find out the effectiveness of the experimental drug, TSR-022 for the treatment of melanomas (a type of skin cancer) and what effects, good and/or bad, TSR-022 has on people with skin cancer. This trial will also evaluate the immune system's response to the drug in your body.
Clinical Study Identifier: s17-00279
ClinicalTrials.gov Identifier: NCTs17-00279
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
